Skorpios Trust

Skorpios Trust (10% owner) sold 3,000,000 shares of STOK at $10.20; stock now at $11.14, -36.4% from 52-week high

A major shareholder divested 3,000,000 shares (-43.4% of pre-transaction holdings) on 2025-06-04 at $10.20, reducing its position from 6.91M to 3.91M shares. The stock has since recovered +28.6% over 30 days and +39.1% over 90 days to $11.14, indicating this sale occurred near a local low; however, it remains -36.4% below the 52-week high of $17.52. At STOK specifically, the insider's two prior sales (2024-12-23 and 2024-09-19) were both well-timed, with 90-day declines of -29.1% and -20.9% respectively, establishing a pattern of selling ahead of downturns at this ticker. The company shows recent profitability (latest quarter: $112.9M net income on $158.6M revenue; annual growth +316.3%) with a modest P/E of 12.11, but was unprofitable over its most recent full fiscal year, creating tension between strong recent results and underlying historical losses that may have prompted the insider's substantial reduction.

Skorpios Trust (10% owner) sells 2,000,000 shares of STOK at $11.50; stock down -36.9% from 52-week high, -7.1% in 30 days

Skorpios Trust, holding 10% of Stoke Therapeutics, sold 2,000,000 shares (22.5% of pre-transaction holdings) for $23,000,000 on 2024-12-23 at $11.50. The stock has declined significantly since the sale, trading at $11.06 (-36.9% from its 52-week high of $17.52) and falling 7.1% over the past 30 days. The company faces challenging fundamentals: negative net income of $-26,430,000 for its most recent full fiscal year, latest quarterly revenue of only $4,894,000, and annual revenue decline of -29.2% year-over-year. At the same ticker (STOK), one of Skorpios's two prior sales was well-timed at the 90-day mark, though the other resulted in a +19.8% gain within 30 days, showing mixed precision on timing. The 2024-09-19 sale preceded a -20.9% 90-day decline, suggesting the current seller has demonstrated some ability to exit before downturns at this specific company.

Skorpios Trust sold 1,937,500 (1.94M shares) of STOK at $14.05 for $27,221,875.00 on 2024-09-19, reducing holdings 17.9%.

Skorpios Trust divested nearly 2M shares—representing a -17.9% reduction in STOK holdings—at $14.05, generating $27.2M in proceeds. The stock has since declined 24.3% from its 52-week high and currently trades at $13.27, 5.6% below the sale price. The company is unprofitable (net income $-25.7M in its most recent full fiscal year) with sharply contracting revenue (-29.2% year-over-year) and minimal quarterly sales of $4.8M, raising fundamental questions about the sustainability of operations. Notably, this is the insider's second sale of STOK shares; a prior April 2024 sale at this ticker was not well-timed at the 90-day mark (the stock did not subsequently fall), and across the insider's broader cross-ticker history, 0.00% of prior sells were well-timed. The magnitude of this reduction—divesting nearly one-fifth of holdings in a micro-cap biotech with deteriorating fundamentals and negative timing patterns—warrants scrutiny of the company's operating trajectory.